GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma
Chinese Academy of Sciences
60 participants
Sep 10, 2021
INTERVENTIONAL
Conditions
Summary
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.
Eligibility
Inclusion Criteria6
- Patients who have been diagnosed with hepatocellular carcinoma.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A/B.
- GPC-3 was validated highly expressed preoperatively.
- Aged 18 to 75, and the expected lifetime is longer than 6 months.
- Approved to sign the informed consent.
Exclusion Criteria6
- Allergic to IRDye800.
- Enrolled in other trials in the past 3 months.
- Another malignant tumor was found.
- Undesirable function of heart, lung, kidney, or any other organs.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
Interventions
Drug Injection: Anti-GPC3-IRDye800CW
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05047510